On July 8, Vertex Pharmaceuticals declined 3.24% in regular trading, trading around $505-506 per share, with turnover of approximately $4.15 billion. The stock continued to face selling pressure following its announcement of the largest acquisition in company history.

On the news front, Vertex Pharmaceuticals announced on July 7 that it will acquire Crinetics Pharmaceuticals at $85 per share in cash, representing a total equity value of approximately $10 billion and a 102% premium over Crinetics' prior closing price. The deal, expected to close in Q3, will be funded through a combination of cash and debt, supported by $4.5 billion in bridge financing from Bank of America and Morgan Stanley. Notably, the acquisition is not expected to contribute positively to Vertex's adjusted operating income until 2029, raising near-term dilution concerns.

The acquisition adds a fifth business pillar — endocrinology — to Vertex's portfolio, with Crinetics' commercialized and Phase 3 assets offering approximately $5 billion in peak sales potential. However, the extended timeline to profitability and integration risks continue to weigh on investor sentiment. RBC Capital has raised its target price on Vertex to $570.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)